An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A new 2026 roundup looked at different ways people are getting NAD+, a molecule that supporters say can help with aging, and how telehealth services are making those options easier to access. The piece compared delivery methods — such as pills, injections, and IV drips — and noted that more online clinics are offering consultations and prescriptions for NAD+ products. It did not claim a miracle; instead it tried to sort out what each approach might actually do and who is offering it. NAD+ (nicotinamide adenine dinucleotide) is a small molecule that cells use in many chemical reactions — think of it as a helper that helps cells make energy and repair damage. Some researchers have found that NAD+ levels fall as we get older, and in lab animals boosting NAD+ can improve certain aspects of health. NAD+ itself doesn’t cross into cells easily, so companies sell related compounds (precursors like nicotinamide riboside or nicotinamide mononucleotide) or offer NAD+ directly by injection or IV. The marketing often frames these as “anti-aging” treatments, but that label covers a wide range of claims and evidence. What the analysis actually shows is a comparison of delivery forms and the business trend of telehealth offering them. Oral precursors are the most convenient and have some clinical studies showing modest increases in blood NAD+ levels and small improvements in metabolic markers in humans. IV or injected NAD+ is more invasive and more expensive; human data on its long-term benefits for aging is limited and mixed. The report likely relied on available trials, expert comment, and the services marketed by clinics rather than presenting a single definitive new clinical trial. That means effect sizes, where they exist, are generally modest and context-dependent — not the dramatic rejuvenation sometimes promised in ads. For someone curious about staying healthy as they get older, the takeaway is practical: if you want to try to support cellular health, starting with oral, well-studied precursors under the guidance of a doctor is the least risky route. Telehealth has made it easier to get a consultation and a prescription, especially for people who live far from specialty clinics. Those considering IV or injected NAD+ should weigh the higher cost and the weaker human-evidence base against the hoped-for benefits, and consider established lifestyle steps — sleep, exercise, balanced diet — that have robust evidence for healthy aging. There are important cautions. Side effects from oral NAD+ precursors are usually mild but can include flushing, nausea, or stomach upset. IV and injectable products carry risks of infection, vein irritation, and reactions to impurities if the product isn’t properly manufactured. Regulation varies by country and by clinic; some telehealth providers operate in gray areas or sell products with limited oversight. People who are pregnant, breastfeeding, on certain medications, or with complex health conditions should not self-prescribe and should consult a clinician. Bottom line: Telehealth is making NAD+ options more available, and different delivery methods carry different trade-offs — oral precursors are safest and best studied in people, while IV and injections are costlier and less proven.
Source: Yahoo Finance